MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells

The discovery of cancer dependencies has the potential to inform therapeutic strategies and to identify putative drug targets. Integrating data from comprehensive genomic profiling of cancer cell lines and from functional characterization of cancer cell dependencies, we discovered that loss of the e...

Full description

Saved in:
Bibliographic Details
Published in:Science (American Association for the Advancement of Science) 2016-03, Vol.351 (6278), p.1214-1218
Main Authors: Kryukov, Gregory V., Wilson, Frederick H., Ruth, Jason R., Paulk, Joshiawa, Tsherniak, Aviad, Marlow, Sara E., Vazquez, Francisca, Weir, Barbara A., Fitzgerald, Mark E., Tanaka, Minoru, Bielski, Craig M., Scott, Justin M., Dennis, Courtney, Cowley, Glenn S., Boehm, Jesse S., Root, David E., Golub, Todd R., Clish, Clary B., Bradner, James E., Hahn, William C., Garraway, Levi A.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The discovery of cancer dependencies has the potential to inform therapeutic strategies and to identify putative drug targets. Integrating data from comprehensive genomic profiling of cancer cell lines and from functional characterization of cancer cell dependencies, we discovered that loss of the enzyme methylthioadenosine phosphorylase (MTAP) confers a selective dependence on protein arginine methyltransferase 5 (PRMT5) and its binding partner WDR77. MTAP is frequently lost due to its proximity to the commonly deleted tumor suppressor gene, CDKN2A. We observed increased intracellular concentrations of methylthioadenosine (MTA, the metabolite cleaved by MTAP) in cells harboring MTAP deletions. Furthermore, MTA specifically inhibited PRMT5 enzymatic activity. Administration of either MTA or a small-molecule PRMT5 inhibitor showed a modest preferential impairment of cell viability for MTAP-null cancer cell lines compared with isogenic MTAP-expressing counterparts. Together, our findings reveal PRMT5 as a potential vulnerability across multiple cancer lineages augmented by a common "passenger" geomic alteration.
ISSN:0036-8075
1095-9203
DOI:10.1126/science.aad5214